Not too expensive, at my dose its around $60/month. Cannot speak for the desensitization from a first hand experience. There is one long term study that lasted two years. I do not believe desensitization was an issue, check out the abstract below. The last sentence says "two year exploratory analysis confirmed the 1-year results."
Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical
Outcomes in Healthy Older Adults
Abstract from the study:
Results: Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects. Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, ��0.5 kg [95% CI, ��1.1 to 0.2 kg] vs. 1.1 kg [CI, 0.7 to 1.5 kg], respectively; P �� 0.001), as did body cell mass, as reflected by intracellular water (change, ��1.0 kg [CI, ��2.1 to 0.2 kg] vs. 0.8 kg [CI, ��0.1 to 1.6 kg], respectively; P �� 0.021). No significant differences were observed in abdominal visceral fat or total fat mass; however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P �� 0.001). Body weight increased 0.8 kg (CI, ��0.3 to 1.8 kg) in the placebo group and 2.7 kg (CI, 2.0 to 3.5 kg) in the MK-677 group (P �� 0.003). Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P �� 0.015), and insulin sensitivity decreased. The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain. Low- density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, ��0.14 mmol/L [CI, ��0.27 to ��0.01 mmol/L]; ��5.4 mg/dL [CI, ��10.4 to ��0.4 mg/ dL]; P �� 0.026); no differences between groups were observed in total or high-density lipoprotein cholesterol levels. Cortisol levels increased 47 nmol/L (CI, 28 to 71 nmol/L (1.7 ��g/dL [CI, 1.0 to 2.6 ��g/dL]) in MK-677 recipients (P �� 0.020). Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients. Increased fat-free mass did not result in changes in strength or function. Two-year exploratory analyses confirmed the 1-year results.
Conclusion: Over 12 months, the ghrelin mimetic MK-677 en- hanced pulsatile growth hormone secretion, significantly increased fat-free mass, and was generally well tolerated. Long-term func- tional and, ultimately, pharmacoeconomic, studies in elderly persons are indicated.
Source:
http://www.annals.org/content/149/9/601.full.pdf
